Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 6Gastrointestinal 4CNS 3Breast 3Plasma cell 2Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Breast Neoplasms 3Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 266Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 146Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Antibodies, Monoclonal × Breast × Clear all
NCT01873833 2023-10-05

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

University of Southern California

Phase 2 Terminated
10 enrolled 16 charts
Breast

Breast Neoplasms

NCT03112590 2023-04-19

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
51 enrolled 13 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00681993 2019-01-22

PBIC

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase NA Completed
35 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡